← Back to Search

Ride Share Program for Prostate Cancer Access

N/A

Waitlist Available

Led By Quoc-Dien Trinh, MD,MBA

Research Sponsored by Brigham and Women's Hospital

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Seeking prostate cancer definitive treatment (surgery or radiation) at the Mass General Brigham Prostate Cancer Outreach Clinic

Intermediate-or high-risk prostate cancer

Timeline

Screening 3 weeks

Treatment Varies

Follow Up within 90 days of diagnosis

Awards & highlights

Study Summary

This trial aims to reduce disparities in prostate cancer treatment access among Black men, increasing health equity and reducing travel burden.

Who is the study for?

This trial is specifically for Black men with intermediate or high-risk prostate cancer who are seeking surgery or radiation at the Mass General Brigham Prostate Cancer Outreach Clinic. Participants should live in areas of Massachusetts with high travel burdens to medical appointments, or personally report transportation challenges.Check my eligibility

What is being tested?

The study is testing a ride share service to see if it helps reduce the difficulty of getting to treatment appointments for prostate cancer patients facing travel hardships. The goal is to improve health equity by making access to care easier.See study design

What are the potential side effects?

Since this trial involves a ride sharing intervention rather than a medical treatment, there are no direct side effects like those associated with drugs or surgical procedures. However, participants may experience issues related to convenience and comfort.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I am looking for a final treatment for prostate cancer, either surgery or radiation, at the Mass General Brigham Prostate Cancer Outreach Clinic.

Select...

My prostate cancer is not low-risk.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ within 90 days of diagnosis

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~within 90 days of diagnosis

This trial's timeline: 3 weeks for screening, Varies for treatment, and within 90 days of diagnosis for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Number of participants receiving definitive treatment within 90 days of diagnosis

Secondary outcome measures

Exit Interview

Rate of Missed appointments

Trial Design

1Treatment groups

Experimental Treatment

Group I: Ride Share ParticipantsExperimental Treatment1 Intervention

Investigators will recruit Black men with intermediate or high-risk PC who are seeking definitive treatment at Mass General Brigham Prostate Cancer Outreach Clinic, as Black men are more likely to report travel burden when accessing care and, therefore, most likely to benefit from ridesharing services. Investigators will implement a pre/post-evaluation design with matched historical controls to estimate the impact of rideshares on reducing missed appointments. Historical controls will be sampled from the pre-intervention period of April 2022 to September 2024 and the post-intervention period between October 2024 and November 2025, where October 2024 represents the initiation of the intervention. Participants who identify as Black, reside in a census tract in Massachusetts, and have been recognized as having a high travel burden based on results from Aim 1 will be eligible to receive the rideshare intervention

0 / 2Eligibility criteria met

Find a Location

Logistics

Travel, including flights, are covered

Your expenses for travel tickets for this trial will be reimbursed.

Who is running the clinical trial?

Brigham and Women's HospitalLead Sponsor

1,611 Previous Clinical Trials

11,470,369 Total Patients Enrolled

21 Trials studying Prostate Cancer

32,622 Patients Enrolled for Prostate Cancer

United States Department of DefenseFED

861 Previous Clinical Trials

227,044 Total Patients Enrolled

38 Trials studying Prostate Cancer

9,054 Patients Enrolled for Prostate Cancer

Dana-Farber Cancer InstituteOTHER

1,079 Previous Clinical Trials

340,798 Total Patients Enrolled

76 Trials studying Prostate Cancer

15,955 Patients Enrolled for Prostate Cancer

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are there still slots available in this research endeavor for participants?

"Clinicaltrials.gov confirms that this particular medical investigation is not actively recruiting participants, as the trial was initially posted on September 1st 2023 and last updated on the 12th of September. Though no longer searching for candidates, there are 1356 other trials looking to enrol patients at present."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Increasing Access to Definitive Treatment for Prostate Cancer

Quoc-Dien Trinh, MD, MBA 2023. "Increasing Access to Definitive Treatment for Prostate Cancer". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT06034431.